United Therapeutics Corporation
UTHR
$307.24
$1.850.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.63% | 25.04% | 23.96% | 26.09% | 20.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.63% | 25.04% | 23.96% | 26.09% | 20.20% |
| Cost of Revenue | 20.27% | 24.26% | 37.38% | 56.24% | 69.85% |
| Gross Profit | 24.04% | 25.14% | 22.46% | 23.12% | 15.99% |
| SG&A Expenses | 34.54% | 21.73% | 23.66% | 10.81% | 0.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.37% | 28.87% | 33.38% | 24.55% | 20.50% |
| Operating Income | 21.95% | 21.26% | 15.26% | 27.65% | 19.92% |
| Income Before Tax | 20.77% | 24.20% | 25.28% | 47.89% | 34.05% |
| Income Tax Expenses | 18.79% | 26.79% | 34.35% | 60.83% | 29.65% |
| Earnings from Continuing Operations | 21.35% | 23.46% | 22.71% | 44.24% | 35.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.35% | 23.46% | 22.71% | 44.24% | 35.40% |
| EBIT | 21.95% | 21.26% | 15.26% | 27.65% | 19.92% |
| EBITDA | 22.56% | 21.48% | 15.30% | 26.53% | 19.12% |
| EPS Basic | 25.66% | 25.97% | 22.46% | 40.71% | 31.54% |
| Normalized Basic EPS | 31.51% | 34.42% | 26.60% | 39.93% | 32.13% |
| EPS Diluted | 24.01% | 25.37% | 22.99% | 42.31% | 31.98% |
| Normalized Diluted EPS | 29.70% | 33.68% | 27.22% | 41.44% | 32.52% |
| Average Basic Shares Outstanding | -3.42% | -1.56% | 0.43% | 2.62% | 2.86% |
| Average Diluted Shares Outstanding | -2.17% | -1.41% | -0.25% | 1.48% | 2.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
